P3 Health Partners and Foresight Acquisition Corp (NASDAQ: FORE) have moved into a new definitive agreement that boosts their status and position.
The renaming undertaking
The two merge to take up the name P3 Health Partners. It is a deal that pushes P3 into the Nasdaq Capital Market. This company remains committed to serving patients, practices, and physicians. The company seems to be abandoning the traditional volume-based strategies. It seems more open to the value-based systems and vows to support such strategies in most business undertakings.
Official’s take on the merger
The CEO of P3, Sherif Abdou, seems rather impressed by the company’s latest move. He sees the move as a major stepping stone in facilitating the transformation of healthcare services. He outlines that they will majorly focus on improving conditions for the payors, patients, and physicians. He supports the company on its quest to support the value-based practices meant to cover the fast-growing Medicare market.
Abdou speaks out about the company in line with its public position, outlining that they will try their best to deliver more differentiated inpatient treatment and care approaches. He encourages all the major stakeholders to check out for the various updates they will be unveiling as time progresses. The official exudes confidence in the company’s outstanding capabilities in the provision of proven care outcomes. The company y wants to spark the kind of change that promotes both provider and patient satisfaction in the long run.
The chairman of Foresight Acquisition Corp, Greg Wasson, also seems quite excited about the latest deal. The official considers P3 to be an ideal company to merge with towards achieving their set goals. This leader admires its deep value-based care expertise, terming it a great “ingredient” to achieving massive business success.
Wasson also elaborately on P3 and its great track record of resolving some of the biggest healthcare challenges.
He considers P3 to be the kind of company that is quite innovative and patient-centric as well. He hopes that the new collaboration that has placed them on Nasdaq will enable them to succeed in delivering enhanced patient outcomes. The official also looks into a future where the merger will cut down on medical costs.